Showing results (31-40 of 51) with videos related to
Sort By:
Pageof 6
Journal of Thoracic Disease|December 23, 2017
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC GroupHervé Le Caer, Isabelle Borget, Romain Corre, et al.Targeted Oncology|May 24, 2019
Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung CancerJean-Bernard Auliac, Karima Saboundji, Michel Andre, et al.Lung Cancer (Amsterdam, Netherlands)|March 3, 2023
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)Alain Vergnenegre, Isabelle Monnet, Charles Ricordel, et al.Interactive Cardiovascular and Thoracic Surgery|March 14, 2015
A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objectiveFabrice Barlesi, Christos Chouaid, Jacky Crequit, et al.BMC Cancer|May 16, 2016
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancerLaura Bonanno, Carlota Costa, Margarita Majem, et al.BMC Cancer|December 17, 2014
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III studyIsabelle Borget, Maurice Pérol, David Pérol, et al.Lung Cancer (Amsterdam, Netherlands)|September 13, 2014
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)Christos Chouaid, Cecile Dujon, Pascal Do, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 26, 2018
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung CancerNiki Karachaliou, Jillian Wilhelmina Paulina Bracht, Manuel Fernandez Bruno, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLCJacek Jassem, Filippo de Marinis, Giuseppe Giaccone, et al.Lung Cancer (Amsterdam, Netherlands)|June 3, 2024
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)Lyria Amari, Pascale Tomasini, Emmanuelle Dantony, et al.Pageof 6